25-OCT-2025 6:10

LEUK ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/
Support		 STUDY R
E
G		 O
P
E
N		 ARM ACCR.
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
SWOG S1905-T-ALL/T-LBL, Rel/Ref, OBI-3424 1 T 1 OBI-3424 8mg 67 5 0 0 0 0 0 02/08/2021 81 41
        2 OBI-3424 10mg   5 0 0 0 0 0      
        3 OBI-3424 12mg   14 6 5 3 0 0      
            24 6 5 3 0 0      
 
  S1925-CLL/SLL, Newly Dx HR, Early vs Delayed V+O 1 Y 1 Delayed V-O 247 57 16 8 5 3 1 03/02/2021 268 93
        2 Early V-O   104 26 11 3 1 0      
            161 42 19 8 4 1      
 
  MM1OA-S03-AML, Newly Dx, Ven+ASTX727 vs Ven+ASTX727+Ena 1 T 1 ASTX727 + Venetoclax + Enasidenib (Safety Run-in) 102 8 8 8 5 2 0 05/16/2025 192 56
            8 8 8 5 2 0      
 
  MM1YA-S01-AML, High Risk, Age <60, 7+3 vs experimental 1 Y 1 Daunorubicin + Cytarabine 335 10 10 7 4 0 0 09/25/2024 281 98
        2 Venetoclax + Daunorubicin + Cytarabine   9 9 6 4 2 1      
        3 Venetoclax + Azacitidine   10 9 7 5 2 1      
        4 (Daunorubicin + Cytarabine) Liposome   11 10 8 6 2 1      
        5 (Daunorubicin + Cytarabine) Liposome + Venetoclax   8 7 6 3 0 0      
            48 45 34 22 6 3      
 
  MYELOMATCH-MSRP for the NCI myeloMATCH Clinical Trials 1 Y 1 Screening   754 667 320 163 50 10 06/18/2024 342 135
            754 667 320 163 50 10      
 
    2 Y 2 Re-screening   67 66 28 16 8 5 06/18/2024    
            67 66 28 16 8 5      
 
    3 Y 3 Re-screening   17 17 13 9 5 3 06/18/2024    
            17 17 13 9 5 3      
 
    4 Y 4 Re-screening   1 1 0 0 0 0 06/18/2024    
            1 1 0 0 0 0      
 
Yes EA9213-T-ALL, dara-hyal for chemo refractory MRD 0 E Total Registrations   6 1 0 0 0 0 02/24/2023 99 33
            6 1 0 0 0 0      
 
    1 E Total Registrations   3 0 0 0 0 0 02/24/2023    
            3 0 0 0 0 0      
 
No A041501-B-Cell ALL, Frontline Tx +/- Intuzumab Ozo 0 E Total Registrations   71 0 0 0 0 0 11/09/2018 263 86
            71 0 0 0 0 0      
 
    1 E Total Registrations   57 0 0 0 0 0 11/09/2018    
            57 0 0 0 0 0      
 
    2 E Total Registrations   44 0 0 0 0 0 11/09/2018    
            44 0 0 0 0 0      
 
  A041703-ALL, Newly Dx, Inotuzumab Ozogamicin + Blinat 0 E Total Registrations   11 0 0 0 0 0 08/13/2020 145 49
            11 0 0 0 0 0      
 
    1 E Total Registrations   5 0 0 0 0 0 08/13/2020    
            5 0 0 0 0 0      
 
  EA9181-ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab 0 E Total Registrations   62 17 10 5 3 2 02/19/2021 168 55
            62 17 10 5 3 2      
 
    1 E Total Registrations   50 13 7 2 2 1 02/19/2021    
            50 13 7 2 2 1      
 
    2 E Total Registrations   43 10 6 3 1 0 02/19/2021    
            43 10 6 3 1 0      
 
  MM1OAEA02-MyeloMATCH: AML, New Dx, Ven+HMA 1 E Total Registrations   9 9 6 4 0 0 12/02/2024 286 98
            9 9 6 4 0 0      
 
  MM1YACTG01-MyeloMATCH: AML, New/Young/Int, Ven+Chemo 1 E Total Registrations   5 3 3 1 0 0 10/14/2024 236 82
            5 3 3 1 0 0      
 

25-OCT-2025 6:10

LEUK Open Studies with No Registrations

Study Registration/Phase Open Date # of
ACT.
INSTs		 # of
CURR
IRBs
21CTP.LEUK01 ALL, Ph+, Asciminib, Dasatinib and Prednisone 1 Initial Registration 15-May-25    
  2 Post-Remission 15-May-25    
  3 Maintenance 15-May-25    
EA9181 ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab 3 Randomization 14-Oct-20 168 55